Transarterial chemoembolization for hepatocellular carcinoma in Fontan surgery patient.

18F-FDG, 2-deoxy-2-[fluorine-18]fluoro- D-glucose Cardiac cirrhosis Congenital heart disease DSA, Digital Subtraction Angiography Fontan operation HCC, hepatocellular carcinoma Hepatocellular carcinoma PET-CT, positron emission tomography TACE, Trans Arterial ChemoEmbolization US, ultrasound ceCT, contrast enhanced Computed Tomography trans-arterial embolization

Journal

Radiology case reports
ISSN: 1930-0433
Titre abrégé: Radiol Case Rep
Pays: Netherlands
ID NLM: 101467888

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 18 08 2020
revised: 29 09 2020
accepted: 30 09 2020
entrez: 22 10 2020
pubmed: 23 10 2020
medline: 23 10 2020
Statut: epublish

Résumé

We describe the case of a 41-year-old woman who developed a liver neoplasm due to previous Fontan surgery for a single ventricle anomaly and pacemaker implantation. She was admitted to our hospital for moderate ascites and she was affected by hepatocellular carcinoma treated by trans-arterial chemoembolization (TACE). Computed tomography showed features of chronic liver disease and 4 cm hepatic nodules with arterial enhancement. Laboratory analyses documented preserved liver function and increased levels of alpha-fetoprotein. TACE was performed obtaining complete necrosis at 4 weeks of follow up and significant reduction of alpha-fetoprotein after 2 months. The patient is currently in follow-up, being evaluated for further treatments and/or combined liver/heart transplantation. TACE is a therapeutic option for the treatment of patients with unresectable HCC and with severe heart disease, like those submitted to FS.

Identifiants

pubmed: 33088372
doi: 10.1016/j.radcr.2020.09.056
pii: S1930-0433(20)30518-5
pmc: PMC7557894
doi:

Types de publication

Case Reports

Langues

eng

Pagination

2602-2606

Informations de copyright

© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington.

Déclaration de conflit d'intérêts

Corresponding authors declare no conflict of interest for all the other authors.

Références

Heart. 2010 Nov;96(21):1750-5
pubmed: 20956491
J Hepatol. 2020 Apr;72(4):702-710
pubmed: 31726116
Insights Imaging. 2018 Jun;9(3):357-367
pubmed: 29623675
N Engl J Med. 2013 May 2;368(18):1756-7
pubmed: 23635071
J Am Coll Cardiol. 2017 Dec 26;70(25):3173-3194
pubmed: 29268929
Curr Probl Diagn Radiol. 2018 Jan - Feb;47(1):19-22
pubmed: 28602501
Tumour Biol. 2015 Dec;36(12):9857-64
pubmed: 26162540
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Medicine (Baltimore). 2019 Aug;98(31):e16557
pubmed: 31374020
Hepatology. 2012 Sep;56(3):1160-9
pubmed: 22383293
Hepatology. 2019 Feb;69(2):911-913
pubmed: 30055116

Auteurs

Antonio Orlacchio (A)

Department of Diagnostic and Interventional Radiology, University Hospital Tor Vergata, Rome, Italy.

Fulvio Gasparrini (F)

Department of Diagnostic and Interventional Radiology, University Hospital Tor Vergata, Rome, Italy.

Ilaria Lenci (I)

Liver Unit, University Hospital Tor Vergata, Rome, Italy.

Maria Giulia Gagliardi (MG)

Department of Cardiology, Division of Grow Up Congenital Heart, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.

Marco Spada (M)

Department of Abdominal Transplantation and Hepatobiliopancreatic Surgery, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.

Manlio Guazzaroni (M)

Department of Diagnostic and Interventional Radiology, University Hospital Tor Vergata, Rome, Italy.

Giorgio Ciccarese (G)

Department of Diagnostic and Interventional Radiology, University Hospital Tor Vergata, Rome, Italy.

Mario Angelico (M)

Liver Unit, University Hospital Tor Vergata, Rome, Italy.

Classifications MeSH